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bjectives This study sought to evaluate the long-term safety of the zotarolimus-eluting stent (ZES)
sing a pooled analysis of pivotal trials.
ackground Drug-eluting stents, compared with bare-metal stents (BMS), have reduced restenosis;
owever, individual trials of these stents have not had sufﬁcient power to ascertain long-term safety.
ethods We combined patient level data from 6 prospective randomized single-arm multicenter
rials involving 2,132 patients treated with ZES and 596 patients treated with a BMS control. The
edian follow-up was 4.1 years, with 5-year follow-up completed in 1,256 patients (97% of those
ligible). The recommended minimum duration of dual antiplatelet therapy in these studies was 3
o 6 months regardless of stent type. An independent events committee adjudicated all events. The
treatment groups were compared after adjustment for between trial variation and for individual
atient clinical and angiographic characteristics by propensity score.
esults The cumulative incidence of adverse events at 5 years for ZES and BMS were: death: 5.9%
ersus 7.6% (adjusted hazard ratio: 0.81, p  0.34), cardiac death: 2.4 versus 3.7% (0.83, p  0.57),
yocardial infarction: 3.4 versus 4.8% (0.77, p  0.37), target lesion revascularization: 7.0% vs. 16.5%
0.42, p  0.001), stent thrombosis (deﬁnite or probable): 0.8 versus 1.7% (0.50, p  0.21). After ad-
ustment for variation in study and patient characteristics, there were no signiﬁcant differences in
tent thrombosis or the clinical safety event rates at 5 years between ZES and BMS.
onclusions Over 5 years, there was no increased risk of death, myocardial infarction, or stent throm-
osis, and there was a beneﬁt of prevention of repeat revascularization procedures in ZES compared
ith BMS. (The ENDEAVOR Pharmacokinetic [PK] Registry: The Medtronic Endeavor Drug Eluting Coro-
ary Stent System [ENDEAVOR PK]; NCT00314275) (The ENDEAVOR II Clinical Trial: The Medtronic
ndeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions [ENDEAVOR II];
CT00614848) (The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial [EN-
EAVOR III]; NCT00217256) (The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in
oronary Artery Lesions [ENDEAVOR IV]; NCT00217269) (J Am Coll Cardiol Intv 2010;3:1240–9)
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1241he treatment of coronary artery obstruction with percuta-
eous placement of coronary stents is associated with relief
f anginal symptoms and infrequent late complications, yet
he effectiveness of bare-metal stents (BMS) is limited by
ntimal hyperplasia and recurrent narrowing of the vessel in
ome patients. Approximately 14% of subjects treated with
MS require repeat percutaneous or surgical revasculariza-
ion procedures to treat restenosis (1). Several DES have
een introduced over the past 7 years, following randomized
linical studies demonstrating their effectiveness at prevent-
ng restenosis within the first year (2–5). However,
ollow-up of patients in these studies has raised concerns
egarding the safety of these stents beyond 1 year (6,7).
urthermore, it has become evident that single studies have
acked sufficient power to ascertain rare events such as late
tent thrombosis (8).
Pooled analysis of multiple studies and implementation of
ierarchical case definitions of adverse events have been
mportant to help understand the relative safety of the
irolimus and paclitaxel drug-eluting stents (DES) (8–10).
hrombosis rates from pooled studies of these stents,
onducted after their approval by U.S. Food and Drug
dministration (FDA) in 2003, have been reported previ-
usly, including data from approximately 800 patients at 4
ears follow-up per DES type (8,10) that showed no
ignificant difference in rates of cardiac death or myocardial
nfarction but a greater number of stent thromboses occur-
ing after the first year in the DES type compared with their
espective BMS control subjects. The FDA has since
pproved additional DES with new metal scaffold materials
nd different polymers and antiproliferative medications
5,11). The agency approved the zotarolimus DES (En-
eavor, Medtronic Cardiovascular, Santa Rosa, California)
n 2008. The stent consists of a cobalt chromium stent
caffold, a phosphorylcholine polymer, and an antiprolifera-
ive rapamycin analogue, zotarolimus. The largest random-
zed trial of this stent compared it to the paclitaxel-eluting
tent and showed noninferiority of the composite of cardiac
eath, target vessel reintervention, and myocardial infarc-
ion at 9 months (11). In a randomized trial where the stent
as compared with BMS, superiority of the zotarolimus-
luting stent (ZES) was shown regarding target vessel
eintervention (2). These trials were part of a series of single
rm and randomized trials of the same stent designed for
DA evaluation, all designed with uniform definitions, and
rospective 5-year follow-up.
We conducted the current study as a pooled patient-level
nalysis of these studies to determine the safety of this new
ES in long-term follow-up. We sought to increase the
ower to detect rare adverse events such as stent thrombosis
y combining multiple individual studies and by employing
niform case definitions. The pooled data are continuously
pdated with results from each contributing trial to monitor
he safety of this approved device. We compared rates of ctent thrombosis, death, and myocardial infarction for the
ES to an identical stent lacking the drug and polymer in
he same studies, after adjusting for between-study and
patient variation.
ethods
tudy design. We pooled the latest available data on clinical
afety outcomes from 6 prospective, multicenter, random-
zed, and single-arm trials evaluating the ZES. Long-term
utcomes following placement of the ZES versus the BMS
ere compared after adjustment for between-trial variation
nd for individual patient clinical and angiographic charac-
eristics by propensity score.
tudy population. The study population includes subjects
nrolled in 6 trials designed as DES registration studies: 3
ingle arm studies—ENDEAVOR I (Multicenter Evalua-
ion of ABT-578 Elution From a Phosphorylcholine-
oated Stent) (12,13), 100 subjects; ENDEAVOR II
Randomized Controlled Trial to Evaluation the Safety and
fficacy of the Medtronic AVE
BT-578 Eluting Driver Coro-
ary Stent in De Novo Native
oronary Artery Lesions) Con-
inued Access Registry (14), 296
ubjects; and ENDEAVOR PK
ENDEAVOR Pharmacokinet-
cs) Study, 43 subjects; and 3 ran-
omized controlled blinded trials,
of which compared the ZES to
he corresponding BMS (Driver,
edtronic)—ENDEAVOR II
2,15), 1,197 subjects; and 2 of
hich compared ZES to ap-
roved DES—ENDEAVOR III (Randomized Controlled
rial of the Medtronic Endeavor Drug-Eluting Coronary
tent System Versus the Cypher Sirolimus-Eluting Coro-
ary Stent System in De Novo Native Coronary Artery
esions) (16,17), 436 subjects, compared against Cypher
Cordis, Warren, New Jersey) and ENDEAVOR IV (Ran-
omized Controlled Trial of the Medtronic Endeavor
rug-Eluting Coronary Stent System Versus the Taxus
aclitaxel-Eluting Coronary Stent System in De Novo
ative Coronary Artery Lesions) (11,18) trials (1,548 sub-
ects, compared against Taxus Express (Boston Scientific,
atick, Massachusetts). Trials included had uniform inclu-
ion/exclusion criteria, end point definitions, adjudication,
nd follow-up procedures. Eligible subjects received treat-
ent of single, previously untreated coronary lesions, as
reviously described. Patients were prescribed aspirin indef-
nitely and clopidogrel for a minimum of 3 months in all
tudies with the exception of 1 randomized study (19) where
ll patients were prescribed a minimum of 6 months of
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
FDA  U.S. Food and Drug
Administration
ZES  zotarolimus-eluting
stent(s)lopidogrel to maintain blinding and consistency with the
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1242nstructions for use of the control paclitaxel-eluting stent.
ll studies were designed with uniform end point defini-
ions, and all patients consented for 5 years of follow-up.
afety end points. The following safety end points were
nalyzed: death, cardiac death, myocardial infarction, car-
iac death or myocardial infarction, and stent thrombosis.
n the study protocols, stent thrombosis was defined as
ngiographic thrombus or subacute closure within the
tented vessel at the time of the clinically driven angio-
raphic restudy for documented ischemia (chest pain and
lectrocardiogram changes), and any death not attributed to
noncardiac cause within the first 30 days was considered a
urrogate for stent thrombosis in the absence of documented
ngiographic stent patency. During the course of these
tudies, the Academic Research Consortium (ARC) (20)
eveloped a uniform and hierarchical classification system
or stent thrombosis, and the FDA recommended use of
his classification system. Definite stent thrombosis required
he presence of an acute coronary syndrome with angio-
raphic or autopsy evidence of thrombus or occlusion.
robable stent thrombosis included unexplained deaths
ithin 30 days after the procedure or acute myocardial
nfarction involving the target-vessel territory without an-
iographic confirmation. All events were adjudicated by an
ndependent clinical events committee using both the orig-
nal protocol definition and the ARC definitions of stent
hrombosis. Additionally, the cumulative incidence of ARC
efinite and probable stent thrombosis was assessed by time
nterval: early (0 to 30 days), late (31 to 360 days), very late
360 days).
tatistical analysis. Descriptive statistics were calculated ac-
ording to treatment for patient demographic, baseline
linical characteristics, and use of dual antiplatelet therapy
DAPT) with aspirin and clopidogrel or ticlopidine through
years.
Patients who did not experience the end point in question
ho pre-maturely withdrew from the study or who had not
et reached the 5-year visit at the time of this analysis were
ensored at the time of last known follow-up. The
roportional-hazards assumption for each treatment was
ssessed using the Kolmogorov-type supremum test (21).
aplan-Meier estimates of the cumulative incidence of
utcomes are presented with 2-sided 95% confidence inter-
als for each treatment. For each end point, treatment
roups were compared on time-to-event using Cox propor-
ional hazards regression adjusting for the following baseline
haracteristics of age, sex, angiographic follow-up assign-
ent, history of smoking, prior percutaneous coronary
ntervention, history of hyperlipidemia, prior myocardial
nfarction, prior coronary artery bypass grafting, worst
ngina category (stable, unstable, and myocardial infarc-
ion), race (white vs. nonwhite), number of diseased vessels,
jection fraction, vessel location, lesion location (proximal,
id, and distal), calcification, TIMI (Thrombolysis In Tyocardial Infarction) flow grade, American College of
ardiology/American Heart Association lesion class B2 or
, reference vessel diameter, minimal lumen diameter, and
esion length, through the use of propensity scores. A
ropensity score (22), calculated for each patient, is the
robability that the patient received ZES or BMS as
redicted by the patient’s covariates. This predicted proba-
ility was calculated using logistic regression with treatment
roup (ZES vs. BMS) as the outcome and the covariates as
he predictors. For any covariates with missing data, those
issing values were replaced with the treatment- and
ex-specific mean (for continuous outcomes) and treatment-
nd sex-specific median (for categorical outcomes) before
reating the propensity score. Patients were then placed into
ontreatment-specific quintiles according to their propen-
ity score. Patients within the same quintiles generally are
onsidered as having similar distributions of the covariates.
he hazard ratio (DES vs. BMS), its 2-sided 95% confi-
ence interval, and a 2-sided test of its significance adjusted
or propensity score quintile are presented for each end
oint. As a secondary analysis for the composite end point
f cardiac death or myocardial infarction and for the end
oint of ARC definite or probable stent thrombosis, we
epeated the propensity-adjusted Cox proportional hazards
egression and recalculated the hazard ratio and confidence
nterval, adding use of DAPT during the study as a
ime-dependent covariate.
The statistical analyses were performed using SAS software
version 9.1, SAS Institute, Inc., Cary, North Carolina).
esults
atient characteristics. The analysis cohort included 2,132
atients treated with ZES and 596 patients treated with a
MS of the same design (Fig. 1) (Table 1) (23,24). The
edian duration of follow-up was 4.01 years in the ZES
roup and 5.06 years in the BMS group. Five-year
ollow-up has been completed in 674 patients (97% of those
ligible) and 582 patients (98%), respectively.
Across treatment groups, most patient and lesion char-
cteristics were similar (Table 2) with a mean reference-
essel diameter of 2.7 mm and mean lesion length of 14
m. A history of diabetes mellitus, smoking, prior percu-
aneous coronary intervention, and triple-vessel coronary
rtery disease were exceptions and were more common in
ES–treated patients. The average ejection fraction was
lso noted to be lower in ZES–treated patients.
linical events. The 5-year cumulative incidence of death,
ardiac death, and myocardial infarction were each similar
cross treatment groups (Figs. 2A to 2C) (Table 3). The
ropensity-adjusted hazard ratios for each of these clinical
vent rates showed no difference between the zotarolimus-
luting and BMS treatment groups for all clinical outcomes.
hese results did not differ using covariate adjustment in
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1243lace of propensity score adjustment. The test of propor-
ional hazards was 0.5 in each case indicating that the
roportional hazards assumption was met.
tent thrombosis. According to the protocol definition or
he ARC definite and probable definition, the cumulative
ncidence of stent thrombosis during 5 years of follow-up
id not differ significantly between ZES and BMS (propen-
ity score-adjusted hazard ratio: 0.38 by protocol definition,
 0.157; 0.50 by ARC definite and probable definition,
 0.21) (Figs. 2D and 2E, Table 4). The cumulative rate
f ARC definite and probable stent thrombosis in ZES over
years and after 1 year and through 5 years of follow-up
ere numerically lower than in BMS (1- to 5-year rates:
.2%, 95% confidence interval: 0.0%, 0.54% vs. 0.4%, 95%
onfidence interval: 0.0%, 0.92%). The test of proportional
azards was 0.7 for both definitions of stent thrombosis
ndicating that the proportional hazards assumption was met.
Among subjects with ARC definite and probable stent
hrombosis, the rates of subsequent mortality and myocar-
ial infarction were 23% (6 of 26) and 77% (20 of 26) overall
nd did not differ between ZES- and BMS-treated subjects
p  0.35).
arget lesion revascularization. The cumulative incidence of
arget lesion revascularization during the 5-year follow-up
eriod was 7.0% of patients with ZES versus 16.5% of
atients with BMS (p  0.001) (Fig. 2F). A risk difference
Figure 1. Study Design
Patients for this analysis were included from the ENDEAVOR trial program and
stent(s); E1  ENDEAVOR I (Multicenter Evaluation of ABT-578 Elution From a
Trial to Evaluate the Safety and Efﬁcacy of the Medtronic AVE ABT-578 Eluting
ENDEAVOR II Continued Access; EIII  ENDEAVOR III (Randomized Controlled T
Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary A
Medtronic Endeavor Drug-Eluting Coronary Stent System Versus the Taxus Pac
trial; EPK  ENDEAVOR PK (Pharmacokinetic) Registry; f/u  follow-up; ZES f 7.8% was observed within the first year of follow-up cnd was sustained (risk difference: 9.5%) at 5 years of
ollow-up.
APT. Dual antiplatelet therapy with aspirin and clopi-
ogrel or ticlopidine was recommended in all but 1 trial for
minimum duration of 3 months. To preserve blinding in
he ENDEAVOR IV trial, which compared the ZES to the
aclitaxel-eluting stent, DAPT was recommended for a
inimum of 6 months. At 1 year, 39% of the ZES–treated
atients and 28% of BMS–treated patients remained on
APT (Table 5). During years 4 and 5 of follow-up, the
ates of DAPT use fell to 10% of subjects for both
reatments.
tent thrombosis and clinical events in ZES versus BMS
fter adjustment for patient characteristics and DAPT.
fter adjustment for DAPT use, there was no difference
etween stent types on all end point comparisons. Spe-
ifically, for cardiac death and myocardial infarction, the
azard ratio was 0.76 (0.50 to 1.16, p  0.20), and for
RC definite or probable stent thrombosis, the hazard
atio was 0.50 (0.17 to 1.48, p  0.21).
iscussion
n the setting of treatment of coronary obstructions to
elieve angina, BMS have been effective, but are limited by
he occurrence of in-stent restenosis. Despite this limita-
ion, the occurrence of life-threatening thrombosis was
d in the identiﬁed groups to the listed end points. BMS  bare-metal
horylcholine-Coated Stent) trial; EII  ENDEAVOR II (Randomized Controlled
r Coronary Stent in De Novo Native Coronary Artery Lesions) trial; EIICA 
the Medtronic Endeavor Drug-Eluting Coronary Stent System Versus the
Lesions) trial; EIV  ENDEAVOR IV (Randomized Controlled Trial of the
-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
limus-eluting stent(s).studie
Phosp
Drive
rial of
rtery
litaxelonsidered be quite rare, occurring at a rate of approximately
Table 1. The ENDEAVOR Clinical Trials
ENDEAVOR I ENDEAVOR II
ENDEAVOR II
Continued Access ENDEAVOR III ENDEAVOR IV ENDEAVOR PK
Study type Multicenter, prospective,
nonrandomized
Multicenter, prospective,
double-blind, randomized
Multicenter, prospective,
nonrandomized
Multicenter, prospective,
randomized
Multicenter, prospective,
randomized
Multicenter, prospective
nonrandomized
Number of patients ZES: 100 ZES: 598; BMS: 599 ZES: 296 ZES: 323; SES: 113 ZES: 773; PES: 775 ZES: 43
Number with
angiographic
follow-up
100 of 100 (100%) 600 of 1,197 (50.1%) 147 of 296 (49.6%) 436 of 436 (100%) 328 of 1,548 (21.2%) 6 of 43 (14.0%)
Lesion criteria Single de novo lesion in native
coronary artery 15 mm in
length and 3.0 to 3.5 mm
in diameter and coverable
with 1 stent
Single de novo lesion in native
coronary artery 14 mm
and 27 mm in length and
2.25 to 3.5 mm in
diameter and coverable
with 1 stent
Single de novo lesion in native
coronary artery 14 mm
and 27 mm in length and
2.25 to 3.5 mm in
diameter and coverable
with 1 stent
Single de novo lesion in native
coronary artery 14 mm
and 27 mm in length and
2.25 to 3.5 mm in
diameter and coverable
with 1 stent
Single de novo lesion in native
coronary artery 27 mm in
length and 2.5 to 3.5 mm
in diameter and coverable
with 1 stent
De novo lesions native
coronary artery 27 mm
in length and 2.5 to
3.5 mm in diameter
Antiplatelet therapy Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 3 months
Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 3 months
Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 3 months
Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 3 months
Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 6 months
Aspirin indeﬁnitely and
clopidogrel or ticlopidine
for 3 months
Planned duration of
follow-up
5 yrs 5 yrs 5 yrs 5 yrs 5 yrs 5 yrs
Follow-up completed 5 yrs 5 yrs 4 yrs 4 yrs 3 yrs 3 yrs
First author (year) (ref. #) Meredith et al. (2005) (23) Fajadet et al. (2006) (2) Schultheiss et al. (2007) (14) Kandzari et al. (2006) (24) Leon et al. (2009) (19) ClinicalTrials.gov identiﬁer:
NCT00314275
ENDEAVOR I Multicenter Evaluation of ABT-578 Elution From a Phosphorylcholine-Coated Stent trial; ENDEAVOR II Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native
Coronary Artery Lesions trial; ENDEAVOR III Randomized Controlled Trial of the Medtronic Endeavor Drug-Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions trail; ENDEAVOR IV
Randomized Controlled Trial of the Medtronic Endeavor Drug-Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions trial; ENDEAVOR PK (Pharmacokinetic) Registry; SES sirolimus-eluting
stent(s).
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1245.6% to 0.7% within the first 30 days after implantation, and
ess frequently thereafter (25,26).
Randomized studies comparing the first drug-eluting
sirolimus- and paclitaxel-eluting) stents to stainless steel
MS demonstrated sustained reductions in clinical resteno-
is rates, yet careful scrutiny revealed higher numbers of
tent thrombosis events in DES occurring after the first year
f follow-up (8,10). These results raised concerns regarding
he long-term safety of DES and reinforced the idea that
he low thrombosis rates observed in BMS remained the
ppropriate benchmark for evaluation of safety of new
tents. The same studies also indicated that the number of
atients required to ascertain rare but serious adverse events
ith any certainty is large and the duration of follow-up
equired is longer than 1 year.
For new coronary stent evaluation, of which 4 types are
DA-approved (3–5,19), the FDA has required pooled
nalysis of all data acquired to detect whether such rare
dverse events are more frequent in comparison with BMS
ither at 1-year or at longer-term follow-up (27). The
nalysis presented here is the result of ongoing monitoring
f the clinical and stent thrombosis event rates for the ZES
elative to a contemporary cobalt chromium BMS of the
ame structural design. We observed no significant differ-
nce in crude or adjusted rates of death, cardiac death,
yocardial infarction, or stent thrombosis to 5 years of
ollow-up in ZES–treated patients compared with BMS–
reated patients. These findings are similar to prior pooled
tudies of randomized studies of other DES compared with
Table 2. Baseline Patient Characteristics
ZES (n  2,132) BMS (n  596)
RVD, mm 2.73 2.76
Lesion length, mm 14.16 14.38
Diabetes mellitus 26.1 22.2
Insulin-dependent diabetes 8.3 7.4
Age, yrs 62.5 10.7 61.9 10.5
Male 71.5 75.3
History of smoking 49.2 35.2
Prior PCI, % 26.0 18.0
Ejection fraction, % 58.9 10.9 60.8 11.8
Angina category
Stable 49.3 50.8
Unstable 40.8 33.8
MI 9.9 15.8
Number of diseased vessels
1 58.8 62.9
2 26.7 26.3
3 14.5 10.7
Values are % or mean SD.
BMSbare-metal stent(s); MImyocardial infarction; PCIpercutaneous coronary interven-
tion; RVD reference vessel diameter; ZES zotarolimus-eluting stent(s).MS (8,10). However, in contradistinction to these studies if other DES, we did observe a smaller number of late stent
hrombosis events in the zotarolimus-eluting versus BMS
omparison.
Each DES differs according to stent platform, polymer,
nd drug type, and, therefore, DES cannot be considered a
rue “class” of therapeutic devices. Although they may be
tructurally similar, stents with different bioactive materials
annot readily be classified to have the same biological
echanism of action. In the case of the ZES represented in
his study, the stent struts and polymer coating are relatively
hinner than prior DES, which has been identified as a
otential mechanism for lower rates of acute myocardial
nfarction due to side branch occlusion (28). The polymer
oating in this case is phosphorylcholine, and in broad
linical experience on non–DES, this coating has not been
ssociated with an increased risk of either restenosis or stent
hrombosis relative to noncoated BMS (29). The drug
otarolimus is an analogue of sirolimus, and yet the elution
inetics of this stent is relatively more rapid than the
irolimus-eluting stent (30). These basic differences in
echanism could explain the similar safety profile of the
ES when compared with BMS. Pre-clinical and detailed
linical studies of the biological response to these stents have
hown earlier cellular coverage of these stents in pre-clinical
tudies (31,32) and clinical intravascular ultrasound (33) and
ptical coherence tomography evaluation (34–35), as well as
ore physiological response to vasoreactive stimuli com-
ared with prior DES (36,37).
It may be difficult to weigh the clinical impact of a rare
ut grave adverse event such as stent thrombosis relative to
he more common but less acute presentation of in-stent
estenosis (38,39). Quantitative comparison with a decision
nalytic model has identified that when comparing drug-
luting with BMS a difference as small as 0.14% per year in
bsolute late stent thrombosis rates over a 4-year period is
ufficient to negate the clinical benefit attributable to reste-
osis prevention (38). In the current study, however, both
tent thrombosis and restenosis were lower for the DES
ver the 5-year follow-up (although not significantly for
tent thrombosis).
It is important to note that the conclusions of any analysis
re limited by the design of the analysis. First, the analysis
erformed was not pre-specified but was requested for the
valuation of safety by the FDA. As such, there was no a
riori definition of noninferiority for the comparison of
ES to BMS. In this setting, it is useful to focus on the
pper and lower confidence limits rather than the p value
lone. Furthermore, although the pooled data achieves a
arger sample size of prospective adjudicated data than
vailable elsewhere, the sample size required to show a stent
hrombosis difference of 1% is 8,000 (40). Second, although
ach trial had similar patient and lesion inclusion require-
ents and characteristics in the enrolled population, not allncluded trials were randomized. The analysis is based on
p
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1246ooling multiple ZES arms, but a single BMS arm. Al-
hough we employed a hierarchical propensity adjusted
odel to adjust for the effects of patient, lesion, and trial
Figure 2. Cumulative Incidence Curves for Major Adverse Events at 5 Year
(A) Cumulative incidence of cardiac death; (B) cumulative incidence of all dea
protocol-deﬁned stent thrombosis; (E) cumulative incidence of deﬁnite and pr
tive incidence of target lesion revascularization. Abbreviations as in Figure 1.
Table 3. 5-Year Cumulative Incidence of Clinical End Points
ZES (n  2,132) 95% CI BMS (
Death 5.9 3.96–7.77
Cardiac death 2.4 1.12–3.63
MI 3.4 1.85–4.86
Cardiac death/MI 5.5 3.64–7.41
Target lesion revascularization 7.0 4.86–9.13CI confidence interval; other abbreviations as in Table 2.haracteristics; it is possible that there are unmeasured
onfounders that result in residual confounding. Third, the
se of DAPT in these trials was predominantly 3- to
cumulative incidence of myocardial infarction; (D) cumulative incidence of
stent thrombosis as deﬁned by Academic Research Consortium; (F) cumula-
96) 95% CI
Adjusted Hazard Ratio
(ZES vs. BMS) 95% CI p Value
5.28–9.97 0.81 0.52–1.25 0.338
1.97–5.37 0.84 0.44–1.57 0.576
2.82–6.74 0.77 0.44–1.35 0.368
5.91–10.92 0.76 0.50–1.16 0.203
13.02–19.97 0.42 0.29–0.60 0.001s
th; (C)
obablen  5
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1247-months duration as the trials pre-dated the current
ecommendations of the American Heart Association/
merican College of Cardiology for 12 months of treat-
ent after DES placement in patients who are not at high
isk of bleeding (41). Overall, in comparing the 2 treatment
roups, because 1 trial compared 2 DES, the duration of
ntiplatelet therapy was on average longer at certain time
oints for ZES. However, after adjustment for DAPT,
here was no significant difference in outcome attributable
o stent type. Finally, this analysis was performed primarily
n the setting of patient with single-vessel treatment. This is
imilar to previous reports of pooled randomized trials of
ther DES to examine stent thrombosis and benefits from a
igh quality of adjudicated data, but may be limited from
he point of generalizability to higher risk patient popula-
ions (8).
Randomized studies are required for definitive determi-
ation of superior safety of different DES. Several trials are
ngoing. Investigators in Denmark compared the sirolimus-
luting stent to the ZES in a randomized trial that em-
loyed the public health system to acquire clinical data in
ollow-up (42). In contrast to the ENDEAVOR III ran-
omized study (14), the rate of myocardial infarction in this
tudy favored the sirolimus-eluting stent. That study, how-
ver, employed an unusual design, using administrative data
ather than clinical follow-up to record myocardial infarc-
ion, which is 1 possible explanation for the discrepant
Table 4. Cumulative Incidence of Stent Thrombosis by Time Interval
ZES (n  2,132) 95% CI BM
Early (0–30 days)
ARC-deﬁned deﬁnite or probable 0.3% 0.09–0.57
Protocol-deﬁned 0.3% 0.09–0.57
Late* (31–360 days)
ARC-deﬁned deﬁnite or probable 0.3% 0.06–0.52
Protocol-deﬁned 0.1% 0.00–0.31
Very late* (361 days–5 yrs)
ARC-deﬁned deﬁnite or probable 0.2% 0.00–0.54
Protocol-deﬁned 0.0% 0.00–0.23
Cumulative (to 5 yrs)
ARC-deﬁned deﬁnite or probable 0.8% 0.06–1.54
Protocol-deﬁned 0.5% 0.00–1.12
*p values not reported for the late/very late intervals because analysis of these intervals does not p
ARC Academic Research Consortium; other abbreviations as in Tables 2 and 3.
Table 5. Dual Antiplatelet Therapy Usage
Proportion of Patients on DAPT at 30 Days 6 Months*
ZES 95.6% 76.2%
BMS 94.2% 61.9%
*The ENDEAVOR I trial did not include a 6-month ascertainment of DAPT usage. Six-month estimateDAPT dual antiplatelet therapy; other abbreviations as in Tables 1, 2, 3, and 4.esults. A large trial that is prospectively designed to
ompare late stent thrombosis rates in the ZES compared
ith the sirolimus-eluting stent is currently underway
PROTECT [Placebo-Controlled Randomized Study of
he Selective A1 Adenosine Receptor Antagonist Rolofyl-
ine for Patients Hospitalized With Acute Decompensated
eart Failure and Volume Overload to Assess Treatment
ffect on Congestion and Renal Function] trial) (43). This
tudy, although randomized, is more broadly inclusive than
he studies pooled in the current analysis and has enrolled a
atient population including treatment of multivessel dis-
ase and acute myocardial infarction. The comparison of
tent thrombosis rates at 3 years is pending follow-up.
The novel aspect to the current analysis of safety of the
ES is that this is the largest and longest-term follow-up of
etailed, prospective, adjudicated data on stent thrombosis
hat is compared in an adjusted fashion to a BMS, consid-
red the benchmark for long-term safety of stents. In this
ooled analysis of clinical trial data examining the long-term
afety of the ZES, comparison to an analogous BMS with
ropensity score adjustment showed no increase in rates of
tent thrombosis, adverse cardiac events, or mortality at 5
ears of follow-up in the largest adjudicated dataset from
egistration trials of a DES. Prospectively designed random-
zed trials are required for definitive determination of safety
ompared with other DES.
 596) 95% CI
Adjusted Hazard Ratio
(ZES vs. BMS) 95% CI p Value
% 0.31–2.04 0.44 0.11–1.72 0.241
% 0.31–2.04 0.44 0.11–1.72 0.241
% 0.00–0.51
% 0.00–0.00
% 0.00–0.92
% 0.00–0.59
% 0.52–2.91 0.50 0.17–1.47 0.211
% 0.30–2.43 0.38 0.10–1.45 0.157
the randomization of individual trials or the adjustment of baseline characteristics.
1 Yr 2 Yrs 3 Yrs 4 Yrs 5 Yrs
8.8% 31.0% 23.7% 7.9% 8.5%
9.0% 13.5% 9.1% 9.2% 8.6%
ased, therefore, on the remaining 5 studies.S (n
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